Triclosan-antibacterial Sutures Efficacy on the Incidence of Surgical Site Infection in Clean-contaminated Wounds

Triclosan-antibacterial Sutures Efficacy on the Incidence of Surgical Site Infection in Clean-contaminated Wounds; Multi-center, Double Blind, Randomized Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04256824

Enrollment

430

Registered

2020-02-05

Start date

2020-02-05

Completion date

2024-01-30

Last updated

2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Site Infection, Surgical Wound, Surgical Wound Infection

Brief summary

Comparing the incidence of SSI in cases using coated Polyglactin 910 suture with Triclosan and cases using Polyglactin 910 suture without Triclosan in clean-contaminated wound surgery

Detailed description

Comparing the incidence of surgical site infection (SSI) in cases using coated Polyglactin 910 suture with Triclosan and cases using Polyglactin 910 suture without Triclosan in clean-contaminated wound surgery. Also, comparing the post hospital stay.

Interventions

DRUGcoated vicryl plus

Coated Polyglactin 910 with Triclosan (coated vicryl plus)

DRUGVicryl

Coated Polyglactin 910 without Triclosan (vicryl)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Intervention model description

randomized-controlled study

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age: 18-75 * clean-contaminated wound surgery

Exclusion criteria

* Patient has immunodeficiency disorder. * Patient receiving anti-cancer / immunosuppressive therapy. * Patients with established pre-operative infection whether community acquired or hospital acquired either at / remote from the operative site.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of surgical site infection	30 days	Incidence of surgical site infection within 30 days

Secondary

Measure	Time frame	Description
Hospital stay	30 days	duration of hospital stay

Countries

Egypt

Contacts

Primary ContactEmad R Issak, Diploma

dr.emad.r.h.issak@gmail.com00201272228989

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026